Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2003;41:663-668
Published online before print December 16, 2002, doi: 10.1161/01.HYP.0000047875.43777.79
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/3/663    most recent
01.HYP.0000047875.43777.79v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, L.
Right arrow Articles by Chen, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L.
Right arrow Articles by Chen, A. F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*VASOPRESSIN
Related Collections
Right arrow Animal models of human disease
Right arrow Other hypertension
Right arrow Hypertension - basic studies
Right arrow Other Vascular biology

(Hypertension. 2003;41:663.)
© 2003 American Heart Association, Inc.


Scientific Contributions

Vasopressin Induces Vascular Superoxide Via Endothelin-1 in Mineralocorticoid Hypertension

Lixin Li; James J. Galligan; Gregory D. Fink; Alex F. Chen

From the Department of Pharmacology and Toxicology, and the Neuroscience Program, Michigan State University, East Lansing.

Correspondence to Dr Alex F. Chen, Department of Pharmacology and Toxicology, B403 Life Sciences Building, Michigan State University, East Lansing, MI 48824-1317. E-mail chenal{at}msu.edu

We have recently reported that endothelin-1 (ET-1), which is increased in the arteries of deoxycorticosterone acetate (DOCA)–salt hypertensive rats, stimulates superoxide production. However, the humoral mechanisms responsible for ET-1–induced superoxide formation in low-renin models of hypertension, such as DOCA-salt hypertension, remain undefined. Vasopressin is known to upregulate vascular preproET-1 gene expression in DOCA-salt rats, an effect that is absent in vasopressin-deficient Brattleboro rats treated with DOCA-salt. The present study tested the hypothesis that vasopressin contributes to ET-1–induced vascular superoxide production in DOCA-salt hypertensive rats. Carotid arterial segments of DOCA, sham (uninephrectomized), or normal (untreated) rats were used for the study. In vitro vasopressin treatment of carotid arteries from normal rats for 24 hours, but not 4 hours, increased both ET-1 and superoxide levels. The increase of vasopressin-induced superoxide was reduced by pretreatment of the vessels with ABT627, a selective ETA receptor antagonist ABT627. Vasopressin, ET-1, and superoxide levels were significant elevated in carotid arteries of DOCA-salt rats compared with sham controls. The selective V1-vasopressin receptor antagonist (ß-Mercapto-ß, ß-cyclopentamethylenepropiony1, O-Me-Tyr2, Arg8 vasopressin, ME-AVP), decreased superoxide both in vasopressin-treated vessels of normal rats and in vessels of DOCA-salt rats, with a concomitant reduction of ET-1 content. These results suggest that vasopressin increases vascular superoxide levels by stimulating ET-1 formation in mineralocorticoid hypertension, and that V1-vasopressin receptors play an important role in this process.


Key Words: vasopressin • endothelin • superoxide • hypertension, low renin




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
K. K. Henderson and K. L. Byron
Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways
J Appl Physiol, April 1, 2007; 102(4): 1402 - 1409.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. E. Cingolani, M. C. Villa-Abrille, M. Cornelli, A. Nolly, I. L. Ennis, C. Garciarena, A. M. Suburo, V. Torbidoni, M. V. Correa, M. C. Camilionde Hurtado, et al.
The Positive Inotropic Effect of Angiotensin II: Role of Endothelin-1 and Reactive Oxygen Species
Hypertension, April 1, 2006; 47(4): 727 - 734.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Vidal, Y. Sun, S. K. Bhattacharya, R. A. Ahokas, I. C. Gerling, and K. T. Weber
Calcium paradox of aldosteronism and the role of the parathyroid glands
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H286 - H294.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. M. Pollock
Endothelin, Angiotensin, and Oxidative Stress in Hypertension
Hypertension, April 1, 2005; 45(4): 477 - 480.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
C. P. del Villar, C. J. G. Alonso, C. A. Feldstein, L. A. Juncos, and J. C. Romero
Role of Endothelin in the Pathogenesis of Hypertension
Mayo Clin. Proc., January 1, 2005; 80(1): 84 - 96.
[Abstract] [PDF]


Home page
CirculationHome page
J.-S. Zheng, X.-Q. Yang, K. J. Lookingland, G. D. Fink, C. Hesslinger, G. Kapatos, I. Kovesdi, and A. F. Chen
Gene Transfer of Human Guanosine 5'-Triphosphate Cyclohydrolase I Restores Vascular Tetrahydrobiopterin Level and Endothelial Function in Low Renin Hypertension
Circulation, September 9, 2003; 108(10): 1238 - 1245.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Li, S. W. Watts, A. K. Banes, J. J. Galligan, G. D. Fink, and A. F. Chen
NADPH Oxidase-Derived Superoxide Augments Endothelin-1-Induced Venoconstriction in Mineralocorticoid Hypertension
Hypertension, September 1, 2003; 42(3): 316 - 321.
[Abstract] [Full Text] [PDF]